Related Experiment Videos
Neuroendocrine tumors. A European view
The American Journal of Medicine
|December 22, 1986
Summary
A Belfast tumor register tracks gastroenteropancreatic endocrine tumors, most commonly carcinoids. Early diagnosis and management, including novel therapies, improve quality of life for patients with these rare, often underdiagnosed, tumors.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Gastroenteropancreatic endocrine tumors (GEP-NETs) are rare and often underdiagnosed.
- Carcinoid tumors are the most frequent type, but insulinomas and gastrinomas also present significant incidence.
- These tumors can be potentially remediable, and metastatic disease does not preclude a good quality of life.
Purpose of the Study:
- To establish and analyze data from a regional tumor register for GEP-NETs.
- To review diagnostic and management strategies for GEP-NETs, focusing on inoperable cases.
- To highlight the importance of recognizing and diagnosing these syndromes due to their treatable nature.
Main Methods:
- Establishment of a dedicated tumor register in Belfast, Northern Ireland.
- Analysis of incidence and types of GEP-NETs within the register.
- Review of current management strategies, including pharmacotherapy and surgical considerations.
Main Results:
- Carcinoid tumors are the most common GEP-NETs.
- Insulinomas, gastrinomas, and unknown types show the highest incidence among non-carcinoid tumors.
- Underdiagnosis is likely due to non-specific presenting symptoms.
Conclusions:
- GEP-NETs are underdiagnosed, necessitating increased awareness and appropriate diagnostic methods.
- Effective management strategies exist, including histamine (H2)-receptor antagonists for Zollinger-Ellison syndrome.
- Tumor growth and endocrine syndromes can be controlled with therapies like streptozotocin and somatostatin analogues, improving patient outcomes.